L19IL2

Phase 3Small molecule

L19IL2 is one of 36 small molecule programs targeting Locally Advanced Basal Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Basal Cell CarcinomaRecruiting

Melanoma Stage IIIRecruiting

NeoadjuvantActive, not recruiting

Locally Advanced Basal Cell CarcinomaPhase 2

Recruiting

Melanoma Stage IIIPhase 2

Recruiting

NeoadjuvantPhase 3

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Neoadjuvant

#DrugCompanyPhaseTrials

Taxol

Teva

Approved

6 2

Opdivo

Bristol-Myers Squibb

Phase 2

6 3

Keytruda

Merck & Co.

Phase 2

2 4

Nubeqa

Bayer

Phase 2

1 5

Ellence

Pfizer

Phase 2

1 6

Vectibix

Amgen

Phase 2

1 7

Femara

Novartis

Phase 2

1 8

Tagrisso

AstraZeneca

Phase 2

1 9

Verzenio

Eli Lilly

Phase 2

1 10

Lenvima

Eisai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Melanoma Stage III

NCT06284590

Q4 2028

Phase 3Active, not recruiting

Neoadjuvant

NCT02938299

Phase 1Recruiting

FAP

NCT06640413

Q1 2031

Phase 2Recruiting

Locally Advanced Basal Cell Carcinoma

NCT07227350

Clinical

Trials by Indication[1]

Neoadjuvant1 trial

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Active, not recruiting·PPhilogen S.p.A.·Phase 3·NCT02938299·214 enrolled

Skin Cancer1 trial

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Unknown status·PPhilogen S.p.A.·Phase 2·NCT04362722·40 enrolled

Metastatic Melanoma1 trial

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Unknown status·PPhilogen S.p.A.·Phase 1/2·NCT02076646·96 enrolled

Advanced Solid Tumours1 trial

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Completed·PPhilogen S.p.A.·Phase 1/2·NCT01058538·33 enrolled

FAP1 trial

A Phase I Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Recruiting·PPhilogen S.p.A.·Phase 1·NCT06640413·56 enrolled

2 more indications

Melanoma Stage III1 trial

A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable Metastases

Recruiting·PPhilogen S.p.A.·Phase 2·NCT06284590·162 enrolled

Locally Advanced Basal Cell Carcinoma1 trial

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07227350·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for L19IL2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L19IL2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L19IL2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Philogen S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPhilogen S.p.A.

L19IL2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q1 2031

Trials by Indication[1]

Neoadjuvant1 trial

Skin Cancer1 trial

Metastatic Melanoma1 trial

Advanced Solid Tumours1 trial

FAP1 trial

Melanoma Stage III1 trial

Locally Advanced Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News